Original title: Effects of the P-Selectin Antagonist Inclacumab on Myocardial Damage After Percutaneous Coronary Intervention for Non–ST-Segment Elevation Myocardial Infarction Results of the SELECT-ACS Trial. Reference: Jean-Claude Tardif et al. J Am Coll Cardiol 2013;61:2048–55.
The pathophysiology of myocardial injury after angioplasty is multifactorial but it is clear that inflammation and platelet activation play a major role. P-selectin is an adhesion molecule that is expressed on endothelial cells and platelets affecting the inflammatory cascade and coagulation.
Inclacumab is a human recombinant monoclonal antibody highly specific anti-P-selectin, so this study was designed to determine the efficacy of the drug in reducing peri-procedural myocardial damage in patients enrolled in acute coronary syndrome without ST segment elevation.
322 patients were randomized to Inclacumab 5 mg/kg, Inclacumab 20 mg/kg or a placebo, all received angioplasty and troponin values
